Neumora Therapeutics, Inc. Common Stock (NMRA) Stock Analysis & Winston Score

Winston Score History

Neumora Therapeutics is a clinical-stage biotech company focused on developing new drugs to treat brain diseases. Its main focus is on conditions like depression, schizophrenia, and other psychiatric disorders that are hard to treat with existing medicines. The company's lead drug candidate, navacaprant, targets a brain receptor called the kappa opioid receptor, which plays a role in mood and emotional processing.

Neumora does not yet sell any products, so it currently earns no revenue. It funds its research through cash raised from investors and partnerships, including backing from Amgen. The company operates primarily in the United States and had a market cap of roughly $300 million as of mid-2026, reflecting the high risk of early-stage drug development. The biggest risk Neumora faces is clinical failure — if navacaprant or its other drug candidates do not prove safe and effective in trials, the company could struggle to survive without additional fundraising.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+30.3% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

66.4%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~9 months

$117M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Cash watch

Neumora Therapeutics, Inc. Common Stock has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-470.9%

Weak — -470.9% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.01

Conservative — low debt load (0.01)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial